Zoledronate upregulates MMP-9 and -13 in rat vascular smooth muscle cells by inducing oxidative stress

Drug Design, Development and Therapy

Volumn 10, Issue , 2016, Pages 1453-1460

  Arun, Mehmet Zuhuri ^a   Reel, Buket ^a   Sala Newby, Graciela B ^b   Bond, Mark ^b   Tsaousi, Aikaterini ^b   Maskell, Perry ^b   Newby, Andrew C ^b  

^a EGE UNIVERSITY   (Turkey)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Bisphosphonate; Matrix metalloproteinase; Reactive oxygen species; Vascular smooth muscle cell; Zoledronate

Indexed keywords

APOCYNIN; COLLAGENASE 3; GELATINASE A; GELATINASE B; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TUMOR NECROSIS FACTOR ALPHA; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CELL STIMULATION; CHEMOLUMINESCENCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION REGULATION; IN VITRO STUDY; MALE; MOLECULAR DYNAMICS; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; UPREGULATION; VASCULAR RING; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; GENETICS; METABOLISM; SPRAGUE DAWLEY RAT; VASCULAR SMOOTH MUSCLE;

ANIMALS; CELLS, CULTURED; DIPHOSPHONATES; IMIDAZOLES; MALE; MATRIX METALLOPROTEINASE 13; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MUSCLE, SMOOTH, VASCULAR; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; RNA, MESSENGER; UP-REGULATION;

EID: 84964561108     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S103124     Document Type: Article

References (32)

1. Ylitalo R, Syvala H, Tuohimaa P, Ylitalo P. Suppression of immunoreactive macrophages in atheromatous lesions of rabbits by clodronate. Pharmacol Toxicol. 2002;90(3):139–143.
2. Ylitalo-Heikkala R. Bisphosphonates and atherosclerosis: why? Lupus. 2006;15(12):903.
3. Bevilacqua M, Dominguez LJ, Rosini S, Barbagallo M. Bisphosphonates and atherosclerosis: why? Lupus. 2005;14(9):773–779.
4. Newby AC, Zaltsman AB. Molecular mechanisms in intimal hyperplasia. J Pathol. 2000;190(3):300–309.
5. Wu L, Zhu L, Shi WH, Zhang J, Ma D, Yu B. Zoledronate inhibits the proliferation, adhesion and migration of vascular smooth muscle cells. Eur J Pharmacol. 2009;602(1):124–131.
6. Albadawi H, Haurani MJ, Oklu R, et al. Differential effect of zoledronic acid on human vascular smooth muscle cells. J Surg Res. 2013;182(2):339–346.
7. Celiloglu M, Aydin Y, Balci P, Kolamaz T. The effect of alendronate sodium on carotid artery intima-media thickness and lipid profile in women with postmenopausal osteoporosis. Menopause. 2009;16(4):689–693.
8. Guzeloglu M, Gul M, Reel B, Yurekli I, Aykut K, Hazan E. The effects of zoledronic acid on neointimal hyperplasia: a rabbit carotid anastomosis model. Anadolu Kardiyol Derg. 2011;11(2):93–100.
9. Santos LL, Cavalcanti TB, Bandeira FA. Vascular effects of bisphosphonates-a systematic review. Clin Med Insights Endocrinol Diabetes. 2012;5:47–54.
10. Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med. 2013;368(21):2004–2013.
11. Newby AC. Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc Res. 2006;69(3):614–624.
12. Green JR. Bisphosphonates: preclinical review. Oncologist. 2004;9 Suppl 4:3–13.
13. Melani C, Sangaletti S, Barazzetta FM, Werb Z, Colombo MP. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res. 2007;67(23):11438–11446.
14. Green JR, Guenther A. The backbone of progress – preclinical studies and innovations with zoledronic acid. Crit Rev Oncol Hematol. 2011;77 Suppl 1:S3–S12.
15. Hewer RC, Sala-Newby GB, Wu YJ, Newby AC, Bond M. PKA and Epac synergistically inhibit smooth muscle cell proliferation. J Mol Cell Cardiol. 2011;50(1):87–98.
16. Bond M, Chase AJ, Baker AH, Newby AC. Inhibition of transcription factor NF-kappaB reduces matrix metalloproteinase-1, -3 and -9 production by vascular smooth muscle cells. Cardiovasc Res. 2001;50(3):556–565.
17. Reel B, Sala-Newby GB, Huang WC, Newby AC. Diverse patterns of cyclooxygenase-independent metalloproteinase gene regulation in human monocytes. Br J Pharmacol. 2011;163(8):1679–1690.
18. Tsaousi A, Williams H, Lyon CA, et al. Wnt4/β-catenin signaling induces VSMC Proliferation and is associated with intimal thickening. Circ Res. 2011;108(4):427–436.
19. Gokce G, Arun MZ. Ergothioneine produces relaxation in isolated rat aorta by inactivating superoxide anion. Eur Rev Med Pharmacol Sci. 2014;18(21):3339–3345.
20. Kishore N, Sommers C, Mathialagan S, et al. A selective IKK-2 inhibitor blocks NF-kappa B-dependent gene expression in interleukin-1 beta-stimulated synovial fibroblasts. J Biol Chem. 2003;278(35):32861–32871.
21. Baldwin AS Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol. 1996;14:649–683.
22. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest. 1996;98(11):2572–2579.
23. Amanso AM, Griendling KK. Differential roles of NADPH oxidases in vascular physiology and pathophysiology. Front Biosci (Schol Ed). 2012;4:1044–1064.
24. Basi DL, Hughes PJ, Thumbigere-Math V, et al. Matrix metalloproteinase-9 expression in alveolar extraction sockets of Zoledronic acid-treated rats. J Oral Maxillofac Surg. 2011;69(11):2698–2707.
25. Valleala H, Hanemaaijer R, Mandelin J, et al. Regulation of MMP-9 (gelatinase B) in activated human monocyte/macrophages by two different types of bisphosphonates. Life Sci. 2003;73(19):2413–2420.
26. Varghese S, Canalis E. Alendronate stimulates collagenase 3 expression in osteoblasts by posttranscriptional mechanisms. J Bone Miner Res. 2000;15(12):2345–2351.
27. Bain J, Plater L, Elliott M, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007;408(3):297–315.
28. Mengshol JA, Vincenti MP, Coon CI, Barchowsky A, Brinckerhoff CE. Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase, and nuclear factor kappaB: differential regulation of collagenase 1 and collagenase 3. Arthritis Rheum. 2000;43(4):801–811.
29. Nagano Y, Matsui H, Shimokawa O, et al. Bisphosphonate-induced gastrointestinal mucosal injury is mediated by mitochondrial superoxide production and lipid peroxidation. J Clin Biochem Nutr. 2012;51(3):196–203.
30. Karabulut AB, Gul M, Karabulut E, Kiran TR, Ocak SG, Otlu O. Oxidant and antioxidant activity in rabbit livers treated with zoledronic acid. Transplant Proc. 2010;42(9):3820–3822.
31. Cheng CY, Hsieh HL, Hsiao LD, Yang CM. PI3-K/Akt/JNK/NF-κ is essential for MMP-9 expression and outgrowth in human limbal epithelial cells on intact amniotic membrane. Stem Cell Res. 2012;9(1):9–23.
32. Bond M, Fabunmi RP, Baker AH, Newby AC. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS Lett. 1998;435(1):29–34.